Product Information

Next Pharmaceuticals Acquires Sytrinol 06/04/2013
SALINAS, CA, Jun 05, 2013  Next Pharmaceuticals has purchased worldwide distribution rights, along with all patents, trademarks and scientific knowledge for Sytrinol from KGK Synergize. Sytrinol is currently sold through Proprietary Nutritionals Inc., who holds distribution rights through December 31, 2013.

PNI to Distribute Sytrinol 12/09/2008

LONDON, Ontario—KGK Synergize selected Kearny, N.J.-based Proprietary Nutritionals Inc. (PNI) as the exclusive worldwide distributor of its proprietary ingredient Sytrinol®, effective Jan. 1, 2009. Sytrinol, a patented combination of polymethoxylated flavones and tocotrienols, has been shown in clinical trials to lower cholesterol by up to 30 percent. PNI’s parent company, Pharmachem Laboratories, will assume manufacturing of Sytrinol to further ensure the ingredient’s quality and consistency.

 

Related Articles:

·         KGK Reclaims Sytrinol License

http://vpico.com/articlemanager/viewstracker.aspx?article=221300&ts=2691789775

Clinical Trials

May 11, 2012
Currently Recruiting....Cholesterol Study ,knee pain and Product Bioavailability

Press Releases

 
August 04,2009    Now Find Sytrinol information @ http://Sytrinol.com
October 20, 2009
KGK Receives Industry Merit Award
November 05, 2009
VITAMIN C WITH METABOLITES REDUCES OXALATE LEVELS COMPARED TO ASCORBIC ACID

Copyright © 2012 KGK Synergize. All rights reserved.